Sökning: onr:"swepub:oai:research.chalmers.se:0c5591fc-88a5-423f-a5f7-06280d5dcda1" >
Benefit of adjuvant...
Benefit of adjuvant interferon alfa-2b (IFN-α) therapy in melanoma patients with high serum MMP-8 levels.
-
Vihinen, Pia (författare)
-
- Tervahartiala, Taina (författare)
- Karolinska Institutet
-
Sorsa, Timo (författare)
-
visa fler...
-
- Hansson, Johan (författare)
- Karolinska Institutet
-
Bastholt, Lars (författare)
-
Aamdal, Steinar (författare)
-
Stierner, Ulrika, 1952 (författare)
-
Pyrhönen, Seppo (författare)
-
Syrjänen, Kari (författare)
-
- Lundin, Johan, 1975 (författare)
- Karolinska Institutet
-
Hernberg, Micaela (författare)
-
visa färre...
-
(creator_code:org_t)
- 2014-10-16
- 2014
- Engelska.
-
Ingår i: Cancer Immunology, Immunotherapy. - : Springer Science and Business Media LLC. - 1432-0851 .- 0340-7004.
- Relaterad länk:
-
http://dx.doi.org/10...
-
visa fler...
-
https://research.cha...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Matrix metalloproteinases (MMPs) are important enzymes in tissue turnover and various inflammatory processes. In this study, it was evaluated whether serum MMP-8 can predict the response to adjuvant interferon alfa-2b (IFN-α) therapy in patients with operated high-risk cutaneous melanoma. Pre-treatment sera from 460 patients with stage IIB-IIIC melanoma were analyzed for MMP-8. The patients were randomized after surgery to adjuvant IFN-α for 12 or 24 months (n = 313) or observation only (n = 147). The median serum MMP-8 level was used to classify the patients into a low MMP-8 (n = 232) and a high MMP-8 (n = 228) group. In the high MMP-8 subgroup, IFN-α therapy significantly improved relapse-free survival (RFS). RFS was 36.8 months in patients with high MMP-8 levels receiving IFN-α therapy, whereas RFS for those with high MMP-8 levels with observation only was 10.6 months (P = 0.027). Median overall survival for patients with high MMP-8 and observation only was 36.7 versus 71.7 months in those receiving IFN-α (P = 0.13). In a multivariate model, IFN-α therapy was a significant predictor of favorable RFS (HR 0.74; 95 % CI 0.55-0.99; P = 0.048), after adjustment for pre-treatment MMP-8 (HR 1.17; 95 % CI 0.88-1.55; P = 0.28), gender (HR 1.16; 95 % CI 0.86-1.56; P = 0.32), age (HR 1.00; 95 % CI 1.00-1.02; P = 0.12), ulceration (HR 1.09; 95 % CI 0.81-1.46; P = 0.58), and the presence of node metastases (HR 1.36; 95 % CI 1.17-1.58; P
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Vihinen, Pia
-
Tervahartiala, T ...
-
Sorsa, Timo
-
Hansson, Johan
-
Bastholt, Lars
-
Aamdal, Steinar
-
visa fler...
-
Stierner, Ulrika ...
-
Pyrhönen, Seppo
-
Syrjänen, Kari
-
Lundin, Johan, 1 ...
-
Hernberg, Micael ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Cancer Immunolog ...
- Av lärosätet
-
Chalmers tekniska högskola
-
Karolinska Institutet